The University of Glasgow uses cookies for analytics. Find out more about our Privacy policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.
Analytical cookies help us improve our website. We use Google Analytics. All data is anonymised.
Clarity helps us to understand our users’ behaviour by visually representing their clicks, taps and scrolling. All data is anonymised.
email:
James.Overell@glasgow.ac.uk
Medicine - Clinical Neuroscience, BRC - Sir Graeme Davies
Brown, J. W. L. et al. (2021) Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a study. Lancet Neurology, 20(9), pp. 709-720. (doi: 10.1016/S1474-4422(21)00179-4)
York, E. N. et al. (2021) MRI-derived g-ratio and lesion severity in newly diagnosed multiple sclerosis. Brain Communications, 3(4), fcab249. (doi: 10.1093/braincomms/fcab249) (PMID:34877533) (PMCID:PMC8643503)
Davidson, A. I., Halstead, S. K., Goodfellow, J. A., Chavada, G., Mallik, A., Overell, J., Lunn, M. P., McConnachie, A. , van Doorn, P. and Willison, H. J. (2017) Inhibition of complement in Guillain-Barré Syndrome: the ICA-GBS study. Journal of the Peripheral Nervous System, 6, pp. 4-12. (doi: 10.1111/jns.12194) (PMID:27801990)
Kavanagh, D. et al. (2016) Type I interferon causes thrombotic microangiopathy by a dose-dependent toxic effect on the microvasculature. Blood, 128(24), pp. 2824-2833. (doi: 10.1182/blood-2016-05-715987) (PMID:27663672)
Fitzpatrick, A.M., Mann, C.A., Barry, S. , Brennan, K., Overell, J.R. and Willison, H.J. (2011) An open label clinical trial of complement inhibition in multifocal motor neuropathy. Journal of the Peripheral Nervous System, 16(2), pp. 84-91. (doi: 10.1111/j.1529-8027.2011.00328.x)
Overell, J.R., Hsieh, S.-T., Odaka, M., Yuki, N. and Willison, H.J. (2007) Treatment for Fisher syndrome, Bickerstaff's brainstem encephalitis and related disorders. Cochrane Database of Systematic Reviews(1), CD004761. (doi: 10.1002/14651858.CD004761.pub2)
Brown, J. W. L. et al. (2021) Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a study. Lancet Neurology, 20(9), pp. 709-720. (doi: 10.1016/S1474-4422(21)00179-4)
York, E. N. et al. (2021) MRI-derived g-ratio and lesion severity in newly diagnosed multiple sclerosis. Brain Communications, 3(4), fcab249. (doi: 10.1093/braincomms/fcab249) (PMID:34877533) (PMCID:PMC8643503)
Davidson, A. I., Halstead, S. K., Goodfellow, J. A., Chavada, G., Mallik, A., Overell, J., Lunn, M. P., McConnachie, A. , van Doorn, P. and Willison, H. J. (2017) Inhibition of complement in Guillain-Barré Syndrome: the ICA-GBS study. Journal of the Peripheral Nervous System, 6, pp. 4-12. (doi: 10.1111/jns.12194) (PMID:27801990)
Kavanagh, D. et al. (2016) Type I interferon causes thrombotic microangiopathy by a dose-dependent toxic effect on the microvasculature. Blood, 128(24), pp. 2824-2833. (doi: 10.1182/blood-2016-05-715987) (PMID:27663672)
Fitzpatrick, A.M., Mann, C.A., Barry, S. , Brennan, K., Overell, J.R. and Willison, H.J. (2011) An open label clinical trial of complement inhibition in multifocal motor neuropathy. Journal of the Peripheral Nervous System, 16(2), pp. 84-91. (doi: 10.1111/j.1529-8027.2011.00328.x)
Overell, J.R., Hsieh, S.-T., Odaka, M., Yuki, N. and Willison, H.J. (2007) Treatment for Fisher syndrome, Bickerstaff's brainstem encephalitis and related disorders. Cochrane Database of Systematic Reviews(1), CD004761. (doi: 10.1002/14651858.CD004761.pub2)